Lin Mei

Lin Mei

Auto-generated profile, based on publicly available information

Lin Mei

Department of Neuroscience and Regenerative Medicine and Department of Neurology

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

8 November 2013 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
CSChengyong Shen
Chengyong Shen
YLYisheng Lu
Yisheng Lu
BZBin Zhang
Bin Zhang
DFDwight Figueiredo
Dwight Figueiredo
JBJonathan Bean
Jonathan Bean
LMLin Mei
Lin Mei
Myasthenia gravis (MG) is the most common disorder affecting the neuromuscular junction (NMJ). MG is frequently caused by autoantibodies against acetylcholine receptor (AChR) and a kinase critical for NMJ formation, MuSK; however, a proportion of MG patients are double-negative for anti-AChR and anti-MuSK antibodies. Recent studies in these subjects have identified autoantibodies against low-density lipoprotein receptor–related protein 4 (LRP4), an agrin receptor also critical for NMJ formation. LRP4 autoantibodies have not previously been implicated in MG pathogenesis. Here we demonstrate that mice immunized with the extracellular domain of LRP4 generated anti-LRP4 antibodies and exhibited MG-associated symptoms, including muscle weakness, reduced compound muscle action potentials (CMAPs), and compromised neuromuscular transmission. Additionally, fragmented and distorted NMJs were evident at both the light microscopic and electron microscopic levels. We found that anti-LRP4 sera decreased cell surface LRP4 levels, inhibited agrin-induced MuSK activation and AChR clustering, and activated complements, revealing potential pathophysiological mechanisms. To further confirm the pathogenicity of LRP4 antibodies, we transferred IgGs purified from LRP4-immunized rabbits into naive mice and found that they exhibited MG-like symptoms, including reduced CMAP and impaired neuromuscular transmission. Together, these data demonstrate that LRP4 autoantibodies induce MG and that LRP4 contributes to NMJ maintenance in adulthood.

15 October 2014 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
ABArnab Barik
Arnab Barik
YLYisheng Lu
Yisheng Lu
ASAnupama Sathyamurthy
Anupama Sathyamurthy
ABAndrew Bowman
Andrew Bowman
CSChengyong Shen
Chengyong Shen
LMLin Mei
Lin Mei
The neuromuscular junction (NMJ) is a synapse between motor neurons and skeletal muscle fibers, and is critical for control of muscle contraction. Its formation requires neuronal agrin that acts by binding to LRP4 to stimulate MuSK. Mutations have been identified inagrin,MuSK, andLRP4in patients with congenital myasthenic syndrome, and patients with myasthenia gravis develop antibodies against agrin, LRP4, and MuSK. However, it remains unclear whether the agrin signaling pathway is critical for NMJ maintenance because null mutation of any of the three genes is perinatal lethal. In this study, we generated imKO mice, a mutant strain whoseLRP4gene can be deleted in muscles by doxycycline (Dox) treatment. Ablation of theLRP4gene in adult muscle enabled studies of its role in NMJ maintenance. We demonstrate that Dox treatment of P30 mice reduced muscle strength and compound muscle action potentials. AChR clusters became fragmented with diminished junctional folds and synaptic vesicles. The amplitude and frequency of miniature endplate potentials were reduced, indicating impaired neuromuscular transmission and providing cellular mechanisms of adult LRP4 deficiency. We showed that LRP4 ablation led to the loss of synaptic agrin and the 90 kDa fragments, which occurred ahead of other prejunctional and postjunctional components, suggesting that LRP4 may regulate the stability of synaptic agrin. These observations demonstrate that LRP4 is essential for maintaining the structural and functional integrity of the NMJ and that loss of muscle LRP4 in adulthood alone is sufficient to cause myasthenic symptoms.

1 May 2013 in Neuron
Verified
Journal Article
Closed access
DYDong-Min Yin
Dong-Min Yin
YCYong-Jun Chen
Yong-Jun Chen
YLYi-Sheng Lu
Yi-Sheng Lu
JBJonathan C. Bean
Jonathan C. Bean
ASAnupama Sathyamurthy
Anupama Sathyamurthy
LMLin Mei
Lin Mei

14 March 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BZBin Zhang
Bin Zhang
CSChengyong Shen
Chengyong Shen
BBBeverly Bealmear
Beverly Bealmear
SRSamia Ragheb
Samia Ragheb
WXWen-Cheng Xiong
Wen-Cheng Xiong
LMLin Mei
Lin Mei
To determine if patients with myasthenia gravis (MG) have antibodies to agrin, a proteoglycan released by motor neurons and is critical for neuromuscular junction (NMJ) formation, we collected serum samples from 93 patients with MG with known status of antibodies to acetylcholine receptor (AChR), muscle specific kinase (MuSK) and lipoprotein-related 4 (LRP4) and samples from control subjects (healthy individuals and individuals with other diseases). Sera were assayed for antibodies to agrin. We found antibodies to agrin in 7 serum samples of MG patients. None of the 25 healthy controls and none of the 55 control neurological patients had agrin antibodies. Two of the four triple negative MG patients (i.e., no detectable AChR, MuSK or LRP4 antibodies, AChR-/MuSK-/LRP4-) had antibodies against agrin. In addition, agrin antibodies were detected in 5 out of 83 AChR+/MuSK-/LRP4- patients but were not found in the 6 patients with MuSK antibodies (AChR-/MuSK+/LRP4-). Sera from MG patients with agrin antibodies were able to recognize recombinant agrin in conditioned media and in transfected HEK293 cells. These sera also inhibited the agrin-induced MuSK phosphorylation and AChR clustering in muscle cells. Together, these observations indicate that agrin is another autoantigen in patients with MG and agrin autoantibodies may be pathogenic through inhibition of agrin/LRP4/MuSK signaling at the NMJ.

2 March 2015 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
LXLei Xiong
Lei Xiong
JJJi-Ung Jung
Ji-Ung Jung
HWHaitao Wu
Haitao Wu
WXWen-Fang Xia
Wen-Fang Xia
JPJin-Xiu Pan
Jin-Xiu Pan
WXWen-Cheng Xiong
Wen-Cheng Xiong
Significance: This study provides in vivo evidence that Lrp4 loss in osteoblast (OB)-lineage cells results in high–bone-mass deficit. Lrp4 in OB-lineage cells is required to reduce serum levels of sclerostin and to facilitate sclerostin inhibition of OB differentiation and function. These results demonstrate that Lrp4 is a critical player in bone-mass homeostasis and support a model that Lrp4 acts as a sclerostin receptor, inhibiting Wnt/β-catenin signaling and promoting receptor activator of nuclear kappa B ligand (RANKL)-induced osteoclastogenesis. As mutations in the Lrp4 gene have been identified in high–bone-mass patients, this study provides pathophysiological insight into relevant high–bone-mass disorders.